Endologix to Present at the Rodman and Renshaw 8th Annual Healthcare Conference
October 31 2006 - 4:00AM
Business Wire
Endologix, Inc. (Nasdaq:ELGX) today announced that Paul McCormick,
president and chief executive officer, will make a presentation to
the investment community at the Rodman and Renshaw 8th Annual
Healthcare Conference on Tuesday, November 7, 2006 at 8:50 a.m.
Eastern time (5:50 a.m. Pacific time) at the Palace Hotel in New
York. Interested investors may gain access to a live audio webcast
and slide presentation via the Internet by visiting the Company�s
Web site at www.endologix.com. The presentation will be available
and archived on the Web site for 30 days. About Endologix
Endologix, Inc. develops and manufactures minimally invasive
treatments for vascular diseases. Endologix's Powerlink System is
an endoluminal stent graft (ELG) for treating abdominal aortic
aneurysms (AAA). AAA is a weakening of the wall of the aorta, the
largest artery in the body, resulting in a balloon-like
enlargement. Once AAA develops, it continues to enlarge and, if
left untreated, becomes increasingly susceptible to rupture. The
overall patient mortality rate for ruptured AAA is approximately
75%, making it the thirteenth leading cause of death in the U.S.
Additional information can be found on Endologix�s Web site at
www.endologix.com. Endologix, Inc. (Nasdaq:ELGX) today announced
that Paul McCormick, president and chief executive officer, will
make a presentation to the investment community at the Rodman and
Renshaw 8th Annual Healthcare Conference on Tuesday, November 7,
2006 at 8:50 a.m. Eastern time (5:50 a.m. Pacific time) at the
Palace Hotel in New York. Interested investors may gain access to a
live audio webcast and slide presentation via the Internet by
visiting the Company's Web site at www.endologix.com. The
presentation will be available and archived on the Web site for 30
days. About Endologix Endologix, Inc. develops and manufactures
minimally invasive treatments for vascular diseases. Endologix's
Powerlink System is an endoluminal stent graft (ELG) for treating
abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of
the aorta, the largest artery in the body, resulting in a
balloon-like enlargement. Once AAA develops, it continues to
enlarge and, if left untreated, becomes increasingly susceptible to
rupture. The overall patient mortality rate for ruptured AAA is
approximately 75%, making it the thirteenth leading cause of death
in the U.S. Additional information can be found on Endologix's Web
site at www.endologix.com.
Endologix (NASDAQ:ELGX)
Historical Stock Chart
From Sep 2024 to Oct 2024
Endologix (NASDAQ:ELGX)
Historical Stock Chart
From Oct 2023 to Oct 2024